| Katherine Michelle Mattingly, PA | |
|
10628 Park Rd, Charlotte, NC 28210-8407 | |
| (704) 667-7070 | |
| Not Available |
| Full Name | Katherine Michelle Mattingly |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 6 Years |
| Location | 10628 Park Rd, Charlotte, North Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003372079 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | 0010-08768 (North Carolina) | Secondary |
| 208M00000X | Hospitalist | 0010-08768 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Carolinas Medical Center-pineville | Charlotte, NC | Hospital |
| Carolinas Medical Center-northeast | Concord, NC | Hospital |
| Carolinas Medical Center/behav Health | Charlotte, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carolinas Physicians Network Inc | 3375449655 | 1613 |
News Archive
A new and early target for treating pulmonary hypertension appears to be an enzyme that's normally key to energy production but destructive in the face of this high blood pressure inside your lungs.
Follow-up data from the landmark SPRINT study of the effect of high blood pressure on cardiovascular disease have confirmed that aggressive blood pressure management - lowering systolic blood pressure to less than 120 mm Hg - dramatically reduces the risk of heart disease, stroke, and death from these diseases, as well as death from all causes, compared to lowering systolic blood pressure to less than 140 mm Hg.
Coventry Health Care, Inc. today reported consolidated operating results for the quarter ended December 31, 2009. Operating revenues totaled $3.4 billion for the quarter with net earnings of $109.1 million, or $0.74 earnings per diluted share (EPS). For the year ended December 31, 2009, total revenues from continuing operations were $13.9 billion with net earnings from continuing operations of $315.3 million, or $2.14 per diluted share.
The Food and Drug Administration in the U.S. has issued a warning against drinking or injecting high-strength hydrogen peroxide products to treat serious diseases such as AIDS.
Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, announced today that three posters on its lead iCALM therapeutic, the first treatment developed utilizing its iSPERSE inhaled drug platform, will be presented at the European Respiratory Society (ERS) Annual Congress taking place September 1-5, 2012, in Vienna, Austria.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Katherine Michelle Mattingly, PA Po Box 19305, Charlotte, NC 28219-9305 Ph: () - | Katherine Michelle Mattingly, PA 10628 Park Rd, Charlotte, NC 28210-8407 Ph: (704) 667-7070 |
News Archive
A new and early target for treating pulmonary hypertension appears to be an enzyme that's normally key to energy production but destructive in the face of this high blood pressure inside your lungs.
Follow-up data from the landmark SPRINT study of the effect of high blood pressure on cardiovascular disease have confirmed that aggressive blood pressure management - lowering systolic blood pressure to less than 120 mm Hg - dramatically reduces the risk of heart disease, stroke, and death from these diseases, as well as death from all causes, compared to lowering systolic blood pressure to less than 140 mm Hg.
Coventry Health Care, Inc. today reported consolidated operating results for the quarter ended December 31, 2009. Operating revenues totaled $3.4 billion for the quarter with net earnings of $109.1 million, or $0.74 earnings per diluted share (EPS). For the year ended December 31, 2009, total revenues from continuing operations were $13.9 billion with net earnings from continuing operations of $315.3 million, or $2.14 per diluted share.
The Food and Drug Administration in the U.S. has issued a warning against drinking or injecting high-strength hydrogen peroxide products to treat serious diseases such as AIDS.
Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, announced today that three posters on its lead iCALM therapeutic, the first treatment developed utilizing its iSPERSE inhaled drug platform, will be presented at the European Respiratory Society (ERS) Annual Congress taking place September 1-5, 2012, in Vienna, Austria.
› Verified 7 days ago